Literature DB >> 16583358

Endomyocardial infiltration by B and NK cells foreshadows the recurrence of cardiac allograft rejection.

C Sorrentino1, A Scarinci, T D'Antuono, M Piccirilli, M Di Nicola, M Pasquale, C Di Iorio, E Di Carlo.   

Abstract

Heart allograft outcome is unpredictable and acute rejection episodes still occur despite the improvement of immunosuppressive regimens. We therefore investigated whether the immunopathological profile of endomyocardial biopsies might underlie the variations in the clinical course of a graft. Biopsies from transplanted patients were analysed by histology, immunohistochemistry (associated with digital image analysis), confocal and electron microscopy to determine the type and the functional state of leukocytes infiltrating the myocardium, together with their ultrastructural features and those of the graft itself. In comparison with biopsies with grade 0R or grade 1R rejection, those from patients with grade 2R rejection displayed significant infiltration of macrophages, T lymphocytes, and CD83+ and DC-SIGN+ dendritic cells. Fifty-seven per cent were invaded by CD20+B lymphocytes, most of which expressed CD69 activation marker and cooperated in interleukin-12 production, and by CD69+CD94+NK cells expressing interferon-gamma. Ultrastructural signs of myocyte degeneration and microvessel rupture by NK cells were frequent. These patients developed recurrent episodes of acute allograft rejection. Endomyocardial B and NK infiltrates are involved in the dynamics of allograft rejection and are associated with a high risk of its recurrence. Immunopathological assessment of endomyocardial biopsies may thus serve to forecast the probable outcome of a heart allograft. Copyright (c) 2006 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16583358     DOI: 10.1002/path.1980

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

Review 1.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 2.  [Heart transplantation. Pathology, clinical work-up and therapy].

Authors:  H A Baba; J Wohlschläger; J Stypmann; N E Hiemann
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

Review 3.  Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring.

Authors:  Michelle A Wood-Trageser; Andrew J Lesniak; Anthony J Demetris
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

Review 4.  Human dendritic cells and transplant outcome.

Authors:  Mario G Solari; Angus W Thomson
Journal:  Transplantation       Date:  2008-06-15       Impact factor: 4.939

5.  Alloimmune activation promotes anti-cancer cytotoxicity after rat liver transplantation.

Authors:  Stéphanie Lacotte; Graziano Oldani; Florence Slits; Lorenzo A Orci; Laura Rubbia-Brandt; Philippe Morel; Gilles Mentha; Christian Toso
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

6.  NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs.

Authors:  Hiroshi Ichise; Seiji Nagano; Takuya Maeda; Masaki Miyazaki; Yuki Miyazaki; Hiroto Kojima; Nobuyo Yawata; Makoto Yawata; Hidenori Tanaka; Hiroh Saji; Kyoko Masuda; Hiroshi Kawamoto
Journal:  Stem Cell Reports       Date:  2017-08-31       Impact factor: 7.765

Review 7.  The Landscape of Digital Pathology in Transplantation: From the Beginning to the Virtual E-Slide.

Authors:  Ilaria Girolami; Anil Parwani; Valeria Barresi; Stefano Marletta; Serena Ammendola; Lavinia Stefanizzi; Luca Novelli; Arrigo Capitanio; Matteo Brunelli; Liron Pantanowitz; Albino Eccher
Journal:  J Pathol Inform       Date:  2019-07-01

Review 8.  Regulatory B cells: an exciting target for future therapeutics in transplantation.

Authors:  Alexandre Nouël; Quentin Simon; Christophe Jamin; Jacques-Olivier Pers; Sophie Hillion
Journal:  Front Immunol       Date:  2014-01-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.